NEW YORK (360Dx) – Backed by a fresh round of financing, Owlstone Medical is intensifying its efforts to bring tests for lung cancer, colorectal cancer, and asthma to market on its Breath Biopsy platform in coming years.
360Dx Premium gives you: ✔ Full site access ✔ Interest-based email alerts ✔ Access to archives
Never miss another important industry story.
Try 360Dx Premium now.
Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
In the last few years several molecular testing methodologies — such as immunohistochemistry, PCR, and sequencing — have been approved by the US Food and Drug Administration to aid in the management of patients with lung cancer.
This webinar will discuss the use of new software tools to support the diagnosis of CTFR-related disorders using next-generation sequencing.
This webinar will provide a first-hand look at how the Dana-Farber Cancer Center is adapting its oncology care strategy in light of the rapidly evolving molecular landscape.
With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.